OTHER IMMUNOLOGY — Sales to customers (Note 9)
Johnson & Johnson OTHER IMMUNOLOGY — Sales to customers (Note 9) increased by 15.0% to $46.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4500.0%, from $1.00M to $46.00M. Over 4 years (FY 2021 to FY 2025), OTHER IMMUNOLOGY — Sales to customers (Note 9) shows an upward trend with a 26.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration or growth of secondary immunology therapies, while a decrease may signal competitive pressure or product lifecycle maturity within this specific portfolio.
Detailed definition
This metric represents the net revenue generated from the sale of pharmaceutical products within the 'Other Immunology'...
Peer comparison
Comparable to secondary immunology or specialty pharmaceutical revenue segments reported by large-cap biopharmaceutical peers, often used to track the contribution of non-blockbuster assets.
jnj_segment_other_immunology_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.00M | $3.00M | $6.00M | $6.00M | $3.00M | $5.00M | $3.00M | $3.00M | $4.00M | $2.00M | $2.00M | $0.00 | $2.00M | $1.00M | $0.00 | $1.00M | $8.00M | $12.00M | $40.00M | $46.00M |
| QoQ Change | — | -57.1% | +100.0% | +0.0% | -50.0% | +66.7% | -40.0% | +0.0% | +33.3% | -50.0% | +0.0% | -100.0% | — | -50.0% | -100.0% | — | +700.0% | +50.0% | +233.3% | +15.0% |
| YoY Change | — | — | — | — | -57.1% | +66.7% | -50.0% | -50.0% | +33.3% | -60.0% | -33.3% | -100.0% | -50.0% | -50.0% | -100.0% | — | +300.0% | >999% | — | >999% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's other immunology — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported other immunology — sales to customers (note 9) of $46.00M in Q1 2026.
- How has Johnson & Johnson's other immunology — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's other immunology — sales to customers (note 9) increased by 4500.0% year-over-year, from $1.00M to $46.00M.
- What is the long-term trend for Johnson & Johnson's other immunology — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's other immunology — sales to customers (note 9) has grown at a 26.3% compound annual growth rate (CAGR), from $24.00M to $61.00M.
- What does other immunology — sales to customers (note 9) mean?
- Net revenue generated from the sale of specialized immunological pharmaceutical products outside of the company's primary flagship brands.